News stories about Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals Holdings earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5981276598981 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of brokerages have recently issued reports on CRBP. Cantor Fitzgerald set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a report on Monday, July 17th. BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a report on Friday. Finally, Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Saturday, May 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $20.50.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ CRBP) traded up 3.79% during mid-day trading on Friday, hitting $6.85. 686,184 shares of the stock were exchanged. Corbus Pharmaceuticals Holdings has a 12 month low of $3.73 and a 12 month high of $10.78. The stock’s market cap is $344.01 million. The stock’s 50 day moving average is $6.22 and its 200-day moving average is $7.04.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 1,001.77%. The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.50 million. On average, analysts anticipate that Corbus Pharmaceuticals Holdings will post ($0.66) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Corbus Pharmaceuticals Holdings (CRBP) Stock Price” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.